Puberty blockers to be banned indefinitely for under-18s across UK

University courses Medicine & Psychology
1

Labour has announced an indefinite UK-wide ban on puberty blockers for under-18s with gender dysphoria, except within clinical trials. Health Secretary Wes Streeting cited advice from the Commission on Human Medicines (CHM), which deemed the drugs unsafe without sufficient evidence of their benefits and risks. The NHS had already restricted their use earlier this year, and the ban now extends to private prescriptions. Current patients can continue treatment, while a clinical trial is set to begin in 2024.

Dr. Hilary Cass, author of a key review on gender care, supported the restrictions, calling puberty blockers “powerful drugs with unproven benefits.” Streeting emphasized the decision was evidence-based and aimed at safeguarding children, while committing to improving trans healthcare overall. Critics, including trans rights charity Mermaids, expressed disappointment, while others viewed the ban as a step forward in child safeguarding.

3 Likes
2

This move, alongside promises to improve trans healthcare overall, signals Labour’s attempt to navigate a complex issue with caution and care. However, the debate remains deeply polarized—some see the ban as a necessary step for safeguarding children, while others view it as a barrier to timely, affirming care for those with gender dysphoria.

What are your thoughts on the balance between safeguarding and ensuring access to necessary healthcare in this situation? Should clinical trials be the only path forward, or is there a middle ground that better supports young people?

1 Like